ProCE Banner Activity

Liquid Biopsy Testing in NSCLC: How, Why, and When

Clinical Thought
Curious about the newer liquid biopsy tests for mutations? Thomas Stinchcombe, MD, shares his thoughts on the appropriate use of these new assays in lung cancer.

Released: August 03, 2016

Expiration: August 02, 2017

Share

Faculty

Thomas Stinchcombe

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Boehringer Ingelheim

Genentech BioOncology

Lilly

Novartis Oncology

Faculty Disclosure

Primary Author

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Thomas Stinchcombe, MD, disclosed that he has received consulting fees from Ariad, Boehringer Ingelheim, Bristol-Myers Squibb, and Celgene.